IceCure is thrilled to be back at the 2024 European Society of Breast Imaging Scientific Meeting. Join us at Booth L5 in Lisbon, Portugal from October 3 – 5.
Are you planning to attend EUSOBI 2024? Meet with us to learn more about the ProSense™ Cryoablation System for the treatment of fibroadenoma and breast cancer. The booth will feature have live demonstrations from expert users and the IceCure team. The team will be on hand to discuss the growing evidence for breast cancer cryoablation and our system advantages.
Have any questions? Want to schedule a meeting? Simply fill out the contact us form on the right-hand side of this page and a member of the IceCure team will get back to you.
Growing Clinical Evidence for Breast Cryoablation at EUSOBI 2024
Co-primary investigator of the landmark ICE3 trial on cryoablation of small, low-risk breast cancer, Dr. Kenneth Tomkovich, will present his abstract during the session on Image Guided Treatment De-Escalation. “Image Guided Cryoablation as a Primary Treatment for Low-Risk Breast Cancers: Results and Imaging Findings of the ICE3 Trial,” on Saturday, October 5th at 14:30 – 15:40 CEST.
ICE3 Trial Highlights:
- Breast remains whole with minimal scarring
- Performed under local anaesthesia with minimal pain
- 96.3% of patients free from local recurrence following treatment with ProSense & hormone therapy*
- 100% physician & patient satisfaction
Several other abstracts featuring ProSense Cryoablation have been accepted to EUSOBI 2024. Be sure to check them out in the poster presentations.
More about ProSense Cryoablation
IceCure Medical is dedicated to giving breast radiologists the choice to provide their patients with an advanced, minimally invasive treatment option for breast cancer with ProSense™ cryoablation. Our liquid nitrogen-based system offers optimal tumour destruction. ProSense™ enables in-office treatment that can be performed in less than an hour with rapid recovery.
We are looking forward to seeing you in Lisbon.
*ICE3 clinical trial results. The breast cancer indication for the ProSense® System is currently under review by the FDA and has not yet received marketing clearance in the US. ProSense™ is cleared for the treatment of breast cancer in the EU and other select markets. Clinical indications vary by region, please contact us for additional details.